NASDAQ:RLMD Relmada Therapeutics (RLMD) Stock Price, News & Analysis $3.60 -0.04 (-1.10%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Relmada Therapeutics Stock (NASDAQ:RLMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Relmada Therapeutics alerts:Sign Up Key Stats Today's Range$3.50▼$3.7550-Day Range$2.40▼$3.6452-Week Range$1.88▼$7.22Volume80,340 shsAverage Volume184,823 shsMarket Capitalization$108.48 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingHold Company OverviewRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Relmada Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks82nd Percentile Overall ScoreRLMD MarketRank™: Relmada Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 197th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingRelmada Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRelmada Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Relmada Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Relmada Therapeutics are expected to grow in the coming year, from ($2.50) to ($2.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relmada Therapeutics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relmada Therapeutics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelmada Therapeutics has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Relmada Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.14% of the outstanding shares of Relmada Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Relmada Therapeutics has recently increased by 5.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.45 Percentage of Shares Shorted4.14% of the outstanding shares of Relmada Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Relmada Therapeutics has recently increased by 5.93%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment-0.55 News SentimentRelmada Therapeutics has a news sentiment score of -0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Relmada Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for RLMD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $429,655.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders18.00% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relmada Therapeutics' insider trading history. Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Stock News HeadlinesLeerink Partnrs Issues Pessimistic Outlook for RLMD EarningsOctober 20, 2024 | americanbankingnews.comRelmada Therapeutics (NASDAQ:RLMD) Stock Quotes, Forecast and News SummaryOctober 14, 2024 | benzinga.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)How To Find The Insider Trades That Consistently Outperform The Market – Under The RadarOctober 10, 2024 | benzinga.comJefferies Upgrades Relmada Therapeutics (RLMD)September 18, 2024 | msn.comRelmada jumps as Jefferies upgrades on a potential turnaround storySeptember 18, 2024 | msn.comKuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmSeptember 16, 2024 | prnewswire.comRelmada therapeutics CEO acquires shares worth over $395kSeptember 13, 2024 | uk.investing.comSee More Headlines RLMD Stock Analysis - Frequently Asked Questions How have RLMD shares performed this year? Relmada Therapeutics' stock was trading at $4.14 on January 1st, 2024. Since then, RLMD stock has decreased by 13.2% and is now trading at $3.5950. View the best growth stocks for 2024 here. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NASDAQ:RLMD) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.24. How do I buy shares of Relmada Therapeutics? Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Relmada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relmada Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), ServiceNow (NOW), General Electric (GE) and Adobe (ADBE). Company Calendar Last Earnings8/07/2024Today10/24/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLMD CUSIPN/A CIK1553643 Webwww.relmada.com Phone(786) 629-1376FaxN/AEmployees10Year Founded2004Price Target and Rating Average Stock Price Target$7.50 High Stock Price Target$13.00 Low Stock Price Target$2.00 Potential Upside/Downside+108.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-108.58% Return on Assets-95.83% Debt Debt-to-Equity RatioN/A Current Ratio7.44 Quick Ratio7.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.84 per share Price / Book1.27Miscellaneous Outstanding Shares30,174,000Free Float24,743,000Market Cap$108.48 million OptionableOptionable Beta0.51 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:RLMD) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.